Hepcludex-Bulevirtide-Gmod
Hepcludex (bulevirtide) is the first approved therapy with an indication specifically for chronic hepatitis D virus (HDV) infection, a severe form of viral hepatitis seen in patients co-infected with hepatitis B virus (HBV). The drug prevents the virus from entering liver cells, which helps prevent further infection and damage to the liver. Hepcludex is a […]
Decnupaz-Pivekimab-Sunirine-Pvzy
Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate (ADC) developed for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic cancer. The therapy delivers a potent cytotoxic payload directly to cancer cells that express CD123, helping to maximize antitumor activity while minimizing damage to healthy tissues. Decnupaz, as a targeted […]
Awiqli-Insulin Icodec-Abae
Awiqli (Insulin Icodec-Abae) is a next-generation, ultra-long-acting basal insulin developed by Novo Nordisk for the treatment of adults with Type 2 Diabetes Mellitus. Designed for once-weekly administration, insulin icodec-abæ forms a stable subcutaneous depot and binds reversibly to albumin, enabling slow, continuous insulin release over an extended period. This unique pharmacokinetic profile helps maintain consistent […]
Avlayah-Tividenofusp Alfa-Eknm
Avlayah is a prescription intravenous therapy used to treat neurological manifestations of Hunter syndrome (MPS II), a rare genetic disorder caused by enzyme deficiency leading to harmful substrate accumulation. Unlike traditional enzyme replacement therapies, Avlayah is designed to cross the blood–brain barrier, allowing delivery of the functional enzyme to both the body and the brain, […]
Loargys-Pegzilarginase-Nbln
Loargys (pegzilarginase-nbln) is indicated for the treatment of Arginase 1 Deficiency (ARG1-D), also known as hyperargininemia, in adult and pediatric patients 2 years of age and older, a rare urea cycle disorder characterized by elevated plasma arginine levels and progressive neurological impairment. Loargys functions as an enzyme replacement therapy, reducing toxic arginine accumulation and helping […]
Keytruda Qlex-Pembrolizumab And Berahyaluronidase Alfa-Pmph
Keytruda Qlex is an FDA-approved subcutaneous formulation of Keytruda developed by Merck & Co. It contains the active immunotherapy molecule pembrolizumab, a PD-1 immune checkpoint inhibitor, combined with berahyaluronidase alfa, an enzyme that enables rapid subcutaneous delivery. Unlike the traditional intravenous (IV) infusion of Keytruda administered over 30 minutes, Keytruda Qlex is given as a […]
Yartemlea-Narsoplimab-Wuug
Yartemlea is a fully human monoclonal antibody that selectively inhibits mannan-binding lectin–associated serine protease-2 (MASP-2), a key enzyme in the lectin pathway of the complement system. It is approved for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) in adults and pediatric patients aged two years and older. By blocking MASP-2, Yartemlea prevents […]
Lerochol-Lerodalcibep-Liga
Lerochol is a novel cholesterol-lowering biologic developed to address unmet needs in the management of hypercholesterolemia. It is indicated as an adjunct to diet and exercise for reducing low-density lipoprotein cholesterol (LDL-C) levels in adults, including those with heterozygous familial hypercholesterolemia (HeFH). It is designed to target PCSK9-mediated pathways, thereby enhancing LDL receptor recycling and […]
Exdensur-Depemokimab-Ulaa
Exdensur (depemokimab-ulaa) is an ultra-long-acting biologic therapy indicated as an add-on maintenance treatment for severe asthma with an eosinophilic phenotype in adults and adolescents aged 12 years and older. It is administered as a subcutaneous injection every six months in addition to standard asthma medications to help reduce the frequency of asthma exacerbations. It is […]
Voyxact-Sibeprenlimab-Szsi
Voyxact® (sibeprenlimab-szsi) is an FDA-approved prescription medicine used to reduce proteinuria (protein in the urine) in adults with primary IgA nephropathy (IgAN) who are at risk of disease progression. This approval is under the FDA’s accelerated approval pathway, based on the reduction of proteinuria. Its long-term impact on slowing kidney function decline is still being […]
